| HOME >> MEDICINE >> TECHNOLOGY |
Table 113: Sanofi-Aventis SA: key facts 196
Table 114: Sanofi-Aventis SA: key financials ($) 197
Table 115: Sanofi-Aventis SA: key financials (€) 197
Table 116: Sanofi-Aventis SA: key financial ratios 198
Table 117: Russia pharmaceuticals market value forecast: $ million, 2010–15 200
Table 118: Russia size of population (million), 2006–10 201
Table 119: Russia gdp (constant 2000 prices, $ billion), 2006–10 201
Table 120: Russia gdp (current prices, $ billion), 2006–10 201
Table 121: Russia inflation, 2006–10 202
Table 122: Russia consumer price index (absolute), 2006–10 202
Table 123: Russia exchange rate, 2006–10 202
Table 124: United Kingdom pharmaceuticals market value: $ million, 2006–10 204
Table 125: United Kingdom pharmaceuticals market segmentation: % share, by value, 2010 205
Table 126: United Kingdom pharmaceuticals market share: % share, by value, 2010 206
Table 127: AstraZeneca PLC: key facts 219
Table 128: AstraZeneca PLC: key financials ($) 221
Table 129: AstraZeneca PLC: key financial ratios 221
Table 130: GlaxoSmithKline Plc: key facts 223
Table 131: GlaxoSmithKline Plc: key financials ($) 225
Table 132: GlaxoSmithKline Plc: key financials (£) 226
Table 133: GlaxoSmithKline Plc: key financial ratios 226
Table 134: Pfizer Inc.: key facts 228
Table 135: Pfizer Inc.: key financials ($) 229
Table 136: Pfizer Inc.: key financial ratios 229
Table 137: United Kingdom pharmaceuticals market value forecast: $ million, 2010–15 231
Table 138: United Kingdom size of population (million), 2006–10 232
Table 139: United Kingdom gdp (constant 2000 prices, $ billion), 2006–10 232
Table 140: United Kingdom gdp (current prices, $ billion), 2006–10 232
Table 141: United Kingdo
'/>"/>
| SOURCE Reportlinker Copyright©2010 PR Newswire. All rights reserved |